Therapeutic Area market research reports by DelveInsight

• Chronic Myelomonocytic Leukaemia- Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Chronic Myelomonocytic Leukaemia- Pipeline Insight, 2023 DelveInsight’s, “Chronic Myelomonocytic Leukaemia- Pipeline Insight, 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the pipeline drug pr ... Read More

• T cell Lymphoma -Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  T cell Lymphoma -Pipeline Insight, 2023 DelveInsight’s, “T-cell Lymphoma -Pipeline Insight, 2023” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in T-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage p ... Read More

• Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023 DelveInsight’s, “Non Muscle Invasive Bladder Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline d ... Read More

• Fibromyalgia- Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Fibromyalgia- Pipeline Insight, 2023 DelveInsight’s, “Fibromyalgia- Pipeline Insight, 2023” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Fibromyalgia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. I ... Read More

• Obsessive-Compulsive Disorder - Market Insight, Epidemiology And Market Forecast - 2032

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Obsessive-Compulsive Disorder - Market Insight, Epidemiology And Market Forecast - 2032 Key Highlights Obsessive-compulsive disorder (OCD) has been given increased attention in DSM-5, receiving its chapter. However, the diagnostic criteria for OCD in DSM-5 remain largely the same as in DSM-IV, requi ... Read More

• Glioblastoma- Pipeline Insight, 2023

  Jul 01, 2023  |  Published by: DelveInsight  |  USD 5,000

  Glioblastoma- Pipeline Insight, 2023 DelveInsight’s, “Glioblastoma- Pipeline Insight, 2023” report provides comprehensive insights about 190+ companies and 200+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. ... Read More

• Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)-inhibitors – Market Insights, Epidemiology and Market Forecast – 2032

  Jun 01, 2023  |  Published by: DelveInsight  |  USD 7,500

  Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)-inhibitors – Market Insights, Epidemiology and Market Forecast – 2032 Key Highlights: In Japan, the contribution of KRAS mutations is lower compared to Western countries like the United States and Europe In the United States, KRASG12C is present in ~ ... Read More

• Brain metastases- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 2,500

  Brain metastases- Pipeline Insight, 2023 DelveInsight’s, “Brain metastases- Pipeline Insight, 2023” report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in Brain metastases pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage ... Read More

• Cervical Intraepithelial Neoplasia- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Cervical Intraepithelial Neoplasia- Pipeline Insight, 2023 DelveInsight’s, “Cervical Intraepithelial Neoplasia- Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Cervical Intraepithelial Neoplasia pipeline landscape. It covers the pipeline dr ... Read More

• Macular Telangiectasia (MacTel) - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,250

  Macular Telangiectasia (MacTel) - Pipeline Insight, 2023 DelveInsight’s, “Macular Telangiectasia (MacTel) - Pipeline Insight, 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Macular Telangiectasia (MacTel) pipeline landscape. It covers the pipeline drug prof ... Read More

• Triple Negative Breast Cancer - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  Triple Negative Breast Cancer - Pipeline Insight, 2023 DelveInsight’s, “Triple Negative Breast Cancer - Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles ... Read More

• Nosocomial Pneumonia- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Nosocomial Pneumonia- Pipeline Insight, 2023 DelveInsight’s, “Nosocomial Pneumonia- Pipeline Insight, 2023” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Nosocomial Pneumonia pipeline landscape. It covers the pipeline drug profiles, including clinical and noncl ... Read More

• Attention-deficit/hyperactivity disorder (ADHD) - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Attention-deficit/hyperactivity disorder (ADHD) - Pipeline Insight, 2023 DelveInsight’s, “Attention Deficit Hyperactivity Disorder- Pipeline Insight, 2023” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Attention Deficit Hyperactivity Disorder pipeline landscape ... Read More

• Alopecia Areata- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Alopecia Areata- Pipeline Insight, 2023 DelveInsight’s, “Alopecia Areata- Pipeline Insight, 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Alopecia Areata pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage pr ... Read More

• Autistic Disorder- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 2,000

  Autistic Disorder- Pipeline Insight, 2023 DelveInsight’s, “Autistic Disorder- Pipeline Insight, 2023” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Autistic Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical st ... Read More

• Anal Cancer - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,250

  Anal Cancer - Pipeline Insight, 2023 DelveInsight’s, “Anal Cancer - Pipeline Insight, 2023” report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in Anal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It a ... Read More

• Neuroendocrine Tumors- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 2,500

  Neuroendocrine Tumors- Pipeline Insight, 2023 DelveInsight’s, “Neuroendocrine Tumors- Pipeline Insight, 2023,” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and n ... Read More

• Metastatic Uveal Melanoma - Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,500

  Metastatic Uveal Melanoma - Pipeline Insight, 2023 DelveInsight’s, “Metastatic Uveal Melanoma - Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Metastatic Uveal Melanoma pipeline landscape. It covers the pipeline drug profiles, including ... Read More

• Primary Open Angle Glaucoma- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 1,250

  Primary Open Angle Glaucoma- Pipeline Insight, 2023 DelveInsight’s, “Primary Open Angle Glaucoma- Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Primary Open Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including ... Read More

• Amyotrophic Lateral Sclerosis- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  Amyotrophic Lateral Sclerosis- Pipeline Insight, 2023 DelveInsight’s, “Amyotrophic Lateral Sclerosis- Pipeline Insight, 2023” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the pipeline drug profiles, ... Read More

• Ovarian Cancer- Pipeline Insight, 2023

  May 01, 2023  |  Published by: DelveInsight  |  USD 3,000

  Ovarian Cancer- Pipeline Insight, 2023 DelveInsight’s, “Ovarian Cancer- Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage pro ... Read More

• Chronic Kidney Disease - Competitive landscape, 2023

  Apr 01, 2023  |  Published by: DelveInsight  |  USD 3,500

  Chronic Kidney Disease - Competitive landscape, 2023 DelveInsight’s, “Chronic Kidney Disease - Competitive landscape, 2023,” report provides comprehensive insights about 75+ companies and 95+ drugs in Chronic Kidney Disease Competitive landscape. It covers the therapeutics assessment by product typ ... Read More

• Glioma - Epidemiology Forecast - 2032

  Apr 01, 2023  |  Published by: DelveInsight  |  USD 3,950

  Glioma - Epidemiology Forecast - 2032 Key Highlights Gliomas are extremely diffuse, infiltrative tumors that impact the surrounding brain tissue. According to the American Association of Neurological Surgeons (AANS), gliomas constitute 78% of malignant brain tumors in adults, making them the most co ... Read More

• Glaucoma - Competitive Landscape, 2023

  Apr 01, 2023  |  Published by: DelveInsight  |  USD 3,250

  Glaucoma - Competitive Landscape, 2023 DelveInsight’s, “Glaucoma - Competitive landscape, 2023,” report provides comprehensive insights about 45+ companies and 50+ drugs in Glaucoma Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and mol ... Read More

• Acute ischemic stroke (AIS) - Epidemiology Forecast - 2032

  Apr 01, 2023  |  Published by: DelveInsight  |  USD 3,950

  Acute ischemic stroke (AIS) - Epidemiology Forecast - 2032 Key Highlights The incidence of ischemic stroke has been increasing in younger adults, largely driven by a rise in diabetes, obesity, and metabolic syndrome in this age group. A sedentary lifestyle is one of the major risk factors for an isc ... Read More

< prev 21 22 23 24 25 26 27 28 29 30 next >